The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
Doctors say they cannot do anything for little Abigail Jones who was born with brain cancer and Down Syndrome so every moment is precious.
Cool spells of sunshine and some showery outbreaks through rest of today.
Did the tragic pictures of Aylan Kurdi dead on a Turkish beach prompt the latest government U-turn?